Literature DB >> 29311384

Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Suzanne Ostrand-Rosenberg1, Catherine Fenselau2.   

Abstract

Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311384      PMCID: PMC5765878          DOI: 10.4049/jimmunol.1701019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  130 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

2.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

3.  Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

Authors:  Athanasios Kotsakis; Malgorzata Harasymczuk; Bastian Schilling; Vasilis Georgoulias; Athanassios Argiris; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2012-04-13       Impact factor: 2.303

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Authors:  Inbal Mishalian; Rachel Bayuh; Liran Levy; Lida Zolotarov; Janna Michaeli; Zvi Gregorio Fridlender
Journal:  Cancer Immunol Immunother       Date:  2013-10-04       Impact factor: 6.968

6.  Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways.

Authors:  Waeowalee Choksawangkarn; Lauren M Graham; Meghan Burke; Sang Bok Lee; Suzanne Ostrand-Rosenberg; Catherine Fenselau; Nathan J Edwards
Journal:  Proteomics       Date:  2016-07       Impact factor: 3.984

Review 7.  Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells.

Authors:  Katrin Moses; Sven Brandau
Journal:  Semin Immunol       Date:  2016-04-07       Impact factor: 11.130

8.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Differential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variants.

Authors:  M R Young; S Aquino; M E Young
Journal:  J Leukoc Biol       Date:  1989-03       Impact factor: 4.962

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  173 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

3.  HuR promotes miRNA-mediated upregulation of NFI-A protein expression in MDSCs during murine sepsis.

Authors:  Isatou Bah; Tuqa Alkhateeb; Ajinkya Kumbhare; Dima Youssef; Zhi Q Yao; Gregory A Hawkin; Charles E McCall; Mohamed El Gazzar
Journal:  Mol Immunol       Date:  2020-05-28       Impact factor: 4.407

Review 4.  The impact of psychosocial stress and stress management on immune responses in patients with cancer.

Authors:  Michael H Antoni; Firdaus S Dhabhar
Journal:  Cancer       Date:  2019-02-15       Impact factor: 6.860

5.  Mannan-binding lectin suppresses growth of hepatocellular carcinoma by regulating hepatic stellate cell activation via the ERK/COX-2/PGE2 pathway.

Authors:  Junru Li; Huifang Li; Yu Yu; Yan Liu; Yunzhi Liu; Qiang Ma; Liyun Zhang; Xiao Lu; Xiang-Yang Wang; Zhengliang Chen; Daming Zuo; Jia Zhou
Journal:  Oncoimmunology       Date:  2018-10-10       Impact factor: 8.110

Review 6.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 7.  Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site.

Authors:  Elaheh Nasrollahzadeh; Sepideh Razi; Mahsa Keshavarz-Fathi; Massimiliano Mazzone; Nima Rezaei
Journal:  Cancer Immunol Immunother       Date:  2020-06-04       Impact factor: 6.968

Review 8.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

9.  Top-Down Proteomic Characterization of Truncated Proteoforms.

Authors:  Dapeng Chen; Lucia Geis-Asteggiante; Fabio P Gomes; Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Proteome Res       Date:  2019-10-03       Impact factor: 4.466

10.  Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization.

Authors:  Jae Young So; Nicolas Skrypek; Howard H Yang; Anand S Merchant; George W Nelson; Wei-Dong Chen; Hiroki Ishii; Jennifer M Chen; Gangqing Hu; Bhagelu R Achyut; Esther C Yoon; Liying Han; Chuanshu Huang; Margaret C Cam; Keji Zhao; Maxwell P Lee; Li Yang
Journal:  Cancer Res       Date:  2020-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.